Lessons on PrEP from the SEARCH study in east Africa
Publication date: Available online 19 February 2020Source: The Lancet HIVAuthor(s): Connie Celum, Jared M Baeten (Source: The Lancet HIV)
Source: The Lancet HIV - February 20, 2020 Category: Infectious Diseases Source Type: research

Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study
This study is registered with ClinicalTrials.gov, NCT01864603.FindingsBetween June 6, 2016, and June 23, 2017, 70 379 community residents 15 years or older who had not previously been diagnosed with HIV were tested during population-level HIV testing. Of these individuals, 69 121 tested HIV-negative, 12 935 of whom had elevated HIV risk (1353 [10%] serodifferent partnership, 6938 [54%] risk score, 4644 [36%] otherwise self-identified risk). 3489 (27%) initiated PrEP, 2865 (82%) of whom did so on the same day as HIV testing and 1733 (50%) of whom were men. PrEP uptake was lower among individuals aged 15–24 years...
Source: The Lancet HIV - February 20, 2020 Category: Infectious Diseases Source Type: research

Shortening HIV vaccine regimens to achieve high coverage
Publication date: Available online 17 February 2020Source: The Lancet HIVAuthor(s): Maria Blasi, Genevieve G Fouda (Source: The Lancet HIV)
Source: The Lancet HIV - February 18, 2020 Category: Infectious Diseases Source Type: research

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22)
In this study, we evaluated the safety, tolerability, and immunogenicity of shorter, simpler regimens of trivalent Ad26.Mos.HIV expressing mosaic HIV-1 Env/Gag/Pol antigens combined with aluminium phosphate-adjuvanted clade C gp140 protein.MethodsWe did this randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) at Beth Israel Deaconess Medical Center in Boston, MA, USA. We included healthy, HIV-uninfected participants (aged 18–50 years) who were considered at low risk for HIV infection and had not received any vaccines in the 14 days before study commencement. We randomly assigned participant...
Source: The Lancet HIV - February 18, 2020 Category: Infectious Diseases Source Type: research

HIV transmission and source–sink dynamics in sub-Saharan Africa
Publication date: Available online 14 February 2020Source: The Lancet HIVAuthor(s): Justin T Okano, Katie Sharp, Eugenio Valdano, Laurence Palk, Sally BlowerSummaryMultiple phylogenetic studies of HIV in sub-Saharan Africa have shown that mobility-driven transmission frequently occurs: many communities export and import strains. Mobility-driven transmission can result in source–sink dynamics: one community can sustain a micro-epidemic in another community in which transmission is too low to be self-sustaining. In epidemiology, the basic reproduction number (R0) is used to specify the sustainability threshold. R0 repr...
Source: The Lancet HIV - February 15, 2020 Category: Infectious Diseases Source Type: research

How universal does universal test and treat have to be?
Publication date: Available online 13 February 2020Source: The Lancet HIVAuthor(s): Rebecca F Baggaley, T Déirdre Hollingsworth (Source: The Lancet HIV)
Source: The Lancet HIV - February 15, 2020 Category: Infectious Diseases Source Type: research

The effect of 90-90-90 on HIV-1 incidence and mortality in eSwatini: a mathematical modelling study
Publication date: Available online 13 February 2020Source: The Lancet HIVAuthor(s): Adam Akullian, Michelle Morrison, Geoffrey P Garnett, Zandile Mnisi, Nomthandazo Lukhele, Daniel Bridenbecker, Anna BershteynSummaryBackgroundThe rapid scale-up of antiretroviral therapy (ART) towards the UNAIDS 90-90-90 goals over the last decade has sparked considerable debate as to whether universal test and treat can end the HIV-1 epidemic in sub-Saharan Africa. We aimed to develop a network transmission model, calibrated to capture age-specific and sex-specific gaps in the scale-up of ART, to estimate the historical and future effect o...
Source: The Lancet HIV - February 15, 2020 Category: Infectious Diseases Source Type: research

Novel approach to scale integrated depression and HIV care
Publication date: Available online 11 February 2020Source: The Lancet HIVAuthor(s): Jerome T Galea, Stephanie Marhefka, Elena Cyrus, Carmen Contreras, Brandon Brown (Source: The Lancet HIV)
Source: The Lancet HIV - February 12, 2020 Category: Infectious Diseases Source Type: research

Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial
Publication date: Available online 6 February 2020Source: The Lancet HIVAuthor(s): Punnee Pitisuttithum, Sorachai Nitayaphan, Suwat Chariyalertsak, Jaranit Kaewkungwal, Peter Dawson, Jittima Dhitavat, Benjaluck Phonrat, Siriwat Akapirat, Nicos Karasavvas, Lindsay Wieczorek, Victoria Polonis, Michael A Eller, Poonam Pegu, Dohoon Kim, Alexandra Schuetz, Surat Jongrakthaitae, Yingjun Zhou, Faruk Sinangil, Sanjay Phogat, Carlos A DiazgranadosSummaryBackgroundThe RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in preventing HIV...
Source: The Lancet HIV - February 8, 2020 Category: Infectious Diseases Source Type: research

Correction to Lancet HIV 2020; published online Jan 14. https://doi.org/10.1016/S2352-3018(19)30378-9
Publication date: Available online 6 February 2020Source: The Lancet HIVAuthor(s): (Source: The Lancet HIV)
Source: The Lancet HIV - February 8, 2020 Category: Infectious Diseases Source Type: research

Vaccine boosts: balancing response magnitude and character
Publication date: Available online 6 February 2020Source: The Lancet HIVAuthor(s): Andrew R Crowley, Margaret E Ackerman (Source: The Lancet HIV)
Source: The Lancet HIV - February 8, 2020 Category: Infectious Diseases Source Type: research

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
Publication date: Available online 5 February 2020Source: The Lancet HIVAuthor(s): Andrew N Phillips, Loveleen Bansi-Matharu, Francois Venter, Diane Havlir, Anton Pozniak, Daniel R Kuritzkes, Annemarie Wensing, Jens D Lundgren, Deenan Pillay, John Mellors, Valentina Cambiano, Andreas Jahn, Tsitsi Apollo, Owen Mugurungi, David Ripin, Juliana Da Silva, Elliot Raizes, Nathan Ford, George K Siberry, Ravindra K GuptaSummaryBackgroundThe integrase inhibitor dolutegravir is being considered in several countries in sub-Saharan Africa instead of efavirenz for people initiating antiretroviral therapy (ART) because of superior tolera...
Source: The Lancet HIV - February 6, 2020 Category: Infectious Diseases Source Type: research

More evidence for dolutegravir as first-line ART for all
Publication date: Available online 5 February 2020Source: The Lancet HIVAuthor(s): Janne Estill, Barbara Bertisch (Source: The Lancet HIV)
Source: The Lancet HIV - February 6, 2020 Category: Infectious Diseases Source Type: research

Time to PrEP for zero HIV transmissions in the UK?
Publication date: Available online 4 February 2020Source: The Lancet HIVAuthor(s): The Lancet HIV (Source: The Lancet HIV)
Source: The Lancet HIV - February 5, 2020 Category: Infectious Diseases Source Type: research

False information on PrEP in direct-to-consumer advertising
Publication date: Available online 4 February 2020Source: The Lancet HIVAuthor(s): Amy S Nunn, William C Goedel, Courtney E Gomillia, Cassandra Sutten Coats, Rupa R Patel, Matthew J Murphy, Christina T Chu, Philip A Chan, Leandro A Mena (Source: The Lancet HIV)
Source: The Lancet HIV - February 5, 2020 Category: Infectious Diseases Source Type: research

Understanding HIV risk and vulnerability among cisgender men with transgender partners
Publication date: Available online 4 February 2020Source: The Lancet HIVAuthor(s): Tonia Poteat, Mannat Malik, Andrea L Wirtz, Erin E Cooney, Sari ReisnerSummaryIn the HIV pandemic, cisgender (ie, non-transgender) men with transgender partners are an underserved population. Complexities of sexuality and gender affect HIV vulnerability for this group, including not identifying with conventional sexual orientation categories (eg, bisexual, heterosexual, or gay) and having attractions based on gender role or expression rather than genital anatomy. Only one HIV prevention interventional study in this population was identified,...
Source: The Lancet HIV - February 5, 2020 Category: Infectious Diseases Source Type: research

The syndemic threat of food insecurity and HIV
Publication date: February 2020Source: The Lancet HIV, Volume 7, Issue 2Author(s): The Lancet HIV (Source: The Lancet HIV)
Source: The Lancet HIV - February 5, 2020 Category: Infectious Diseases Source Type: research

On-demand PrEP efficacy: forgiveness or timely dosing
Publication date: February 2020Source: The Lancet HIV, Volume 7, Issue 2Author(s): Jean-Jacques Parienti (Source: The Lancet HIV)
Source: The Lancet HIV - February 5, 2020 Category: Infectious Diseases Source Type: research

Antiretroviral resistance and management after pre-exposure to prophylaxis
Publication date: February 2020Source: The Lancet HIV, Volume 7, Issue 2Author(s): Victoria Tittle, Marta Boffito, Alan McOwan, Gary Whitlock, Dean Street Collaborative Group (Source: The Lancet HIV)
Source: The Lancet HIV - February 5, 2020 Category: Infectious Diseases Source Type: research

Conditional economic incentives to improve HIV prevention
Publication date: February 2020Source: The Lancet HIV, Volume 7, Issue 2Author(s): Mark K U Pasayan, Adeyinka A Alabi, Douglas F Nixon (Source: The Lancet HIV)
Source: The Lancet HIV - February 5, 2020 Category: Infectious Diseases Source Type: research

PrEP use falling short in African American and Hispanic MSM
Publication date: February 2020Source: The Lancet HIV, Volume 7, Issue 2Author(s): Tony Kirby (Source: The Lancet HIV)
Source: The Lancet HIV - February 5, 2020 Category: Infectious Diseases Source Type: research

Novel metric for evaluating pre-exposure prophylaxis programme effectiveness in real-world settings
Publication date: Available online 31 January 2020Source: The Lancet HIVAuthor(s): Cheryl Hendrickson, Lawrence Long, David van de Vijver, Charles Boucher, Heidi O'Bra, Cassidy W Claassen, Mwansa Njelesani, Crispin Moyo, Daliso B Mumba, Hasina Subedar, Lloyd Mulenga, Sydney Rosen, Brooke E NicholsSummaryAlthough large-scale provision of HIV pre-exposure prophylaxis (PrEP) is gaining momentum, no systematic method to evaluate or compare the effectiveness of different scale-up strategies in real-world settings exists. To date, estimating the effectiveness of PrEP has relied on clinical trials or mathematical models. We propo...
Source: The Lancet HIV - February 1, 2020 Category: Infectious Diseases Source Type: research

Correction to Lancet HIV 2019; 6: e71–72
Publication date: Available online 28 January 2020Source: The Lancet HIVAuthor(s): (Source: The Lancet HIV)
Source: The Lancet HIV - January 30, 2020 Category: Infectious Diseases Source Type: research

Correction to Lancet HIV 2019; 6: e105–15
Publication date: Available online 28 January 2020Source: The Lancet HIVAuthor(s): (Source: The Lancet HIV)
Source: The Lancet HIV - January 30, 2020 Category: Infectious Diseases Source Type: research

Responding to expanding HIV epidemics in Cebu, Philippines
Publication date: Available online 16 January 2020Source: The Lancet HIVAuthor(s): Nicholas A Medland, Peter Banys, Van Phillip Baton, Johann Nadela, Lisa Maher, Ilya Tac-An (Source: The Lancet HIV)
Source: The Lancet HIV - January 17, 2020 Category: Infectious Diseases Source Type: research

Time, population mobility, and HIV transmission
Publication date: Available online 14 January 2020Source: The Lancet HIVAuthor(s): Susan Cassels (Source: The Lancet HIV)
Source: The Lancet HIV - January 15, 2020 Category: Infectious Diseases Source Type: research

Quantifying HIV transmission flow between high-prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda
Publication date: Available online 14 January 2020Source: The Lancet HIVAuthor(s): Oliver Ratmann, Joseph Kagaayi, Matthew Hall, Tanya Golubchick, Godfrey Kigozi, Xiaoyue Xi, Chris Wymant, Gertrude Nakigozi, Lucie Abeler-Dörner, David Bonsall, Astrid Gall, Anne Hoppe, Paul Kellam, Jeremiah Bazaale, Sarah Kalibbala, Oliver Laeyendecker, Justin Lessler, Fred Nalugoda, Larry W Chang, Tulio de OliveiraSummaryBackgroundInternational and global organisations advocate targeting interventions to areas of high HIV prevalence (ie, hotspots). To better understand the potential benefits of geo-targeted control, we assessed the ex...
Source: The Lancet HIV - January 15, 2020 Category: Infectious Diseases Source Type: research

Correction to Lancet HIV 2019; 6: e737–49
Publication date: Available online 9 January 2020Source: The Lancet HIVAuthor(s): (Source: The Lancet HIV)
Source: The Lancet HIV - January 10, 2020 Category: Infectious Diseases Source Type: research

HIV-related stigma among health-care workers in the MENA region
Publication date: Available online 9 January 2020Source: The Lancet HIVAuthor(s): Tala Ballouz, Nour Gebara, Nesrine Rizk (Source: The Lancet HIV)
Source: The Lancet HIV - January 10, 2020 Category: Infectious Diseases Source Type: research

Women in Kenya face challenges to adherence
Publication date: January 2020Source: The Lancet HIV, Volume 7, Issue 1Author(s): Christabel Ligami (Source: The Lancet HIV)
Source: The Lancet HIV - January 7, 2020 Category: Infectious Diseases Source Type: research

Highlights of the 17th European AIDS Conference
Publication date: January 2020Source: The Lancet HIV, Volume 7, Issue 1Author(s): Philippa Harris (Source: The Lancet HIV)
Source: The Lancet HIV - January 7, 2020 Category: Infectious Diseases Source Type: research

People have the power
Publication date: January 2020Source: The Lancet HIV, Volume 7, Issue 1Author(s): The Lancet HIV (Source: The Lancet HIV)
Source: The Lancet HIV - January 7, 2020 Category: Infectious Diseases Source Type: research

Tough requirements for new antiretroviral drugs
Publication date: Available online 3 January 2020Source: The Lancet HIVAuthor(s): Carmen de Mendoza, Vicente Soriano (Source: The Lancet HIV)
Source: The Lancet HIV - January 4, 2020 Category: Infectious Diseases Source Type: research

Influenza vaccine in pregnant women with HIV: are we there?
Publication date: Available online 3 January 2020Source: The Lancet HIVAuthor(s): Sharon Nachman (Source: The Lancet HIV)
Source: The Lancet HIV - January 4, 2020 Category: Infectious Diseases Source Type: research

Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial
This study assessed the immunogenicity and safety of different dosing schedules of inactivated influenza vaccine in pregnant women living with HIV in South Africa.MethodsIn this double-blind, randomised, controlled trial, we recruited pregnant women with HIV from seven antenatal clinics in Soweto, South Africa. Pregnant women were eligible if they were aged 18–38 years, infected with HIV, and had an estimated gestational age of 12–36 weeks. Women were randomly assigned (1:1:1), using a computer-generated randomisation list, to receive inactivated influenza vaccine containing 15 μg of each of the three season...
Source: The Lancet HIV - January 4, 2020 Category: Infectious Diseases Source Type: research

Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
This study is registered with ClinicalTrials.gov, NCT02217904, and EudraCT, 2014-002192-28.FindingsBetween Sept 17, 2015, and May 11, 2017, we enrolled 30 participants (six per panel). Islatravir was generally well tolerated. 27 (90%) participants had 60 adverse events after receipt of drug, of which 21 (35%) were deemed to be drug related. The most common (n>1) drug-related adverse events were headache (in nine [30%] participants) and diarrhoea (in two [7%]). No serious adverse events were reported, and no participants discontinued due to an adverse event. Plasma islatravir pharmacokinetics and intracellular islatravir...
Source: The Lancet HIV - January 4, 2020 Category: Infectious Diseases Source Type: research

No excuses left to delay opioid agonist treatment roll-out
Publication date: Available online 23 December 2019Source: The Lancet HIVAuthor(s): Ruslan Malyuta, Reinhard M Krausz (Source: The Lancet HIV)
Source: The Lancet HIV - December 24, 2019 Category: Infectious Diseases Source Type: research

Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study
Publication date: Available online 23 December 2019Source: The Lancet HIVAuthor(s): Jiale Tan, Frederick L Altice, Lynn M Madden, Alexei ZelenevSummaryBackgroundAs HIV incidence and mortality continue to increase in eastern Europe and central Asia, particularly among people who inject drugs (PWID), it is crucial to effectively scale-up opioid agonist therapy (OAT), such as methadone or buprenorphine maintenance therapy, to optimise HIV outcomes. With low OAT coverage among PWID, we did an optimisation assessment using current OAT procurement and allocation, then modelled the effect of increased OAT scale-up on HIV incidenc...
Source: The Lancet HIV - December 24, 2019 Category: Infectious Diseases Source Type: research

Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV
Publication date: Available online 20 December 2019Source: The Lancet HIVAuthor(s): Robert C Bollinger, Chloe L Thio, Mark S Sulkowski, Jane McKenzie-White, David L Thomas, Charles FlexnerSummaryThe first long-acting formulations of HIV drugs are undergoing regulatory review for use in maintenance of viral suppression in people with HIV. Although these novel drug formulations could contribute greatly to HIV treatment and prevention efforts, their lack of activity against hepatitis B virus (HBV) could limit their global impact, particularly in populations with high burdens of both HIV and HBV. An urgent need for greater inv...
Source: The Lancet HIV - December 21, 2019 Category: Infectious Diseases Source Type: research

Adherence among post-partum women living with HIV
Publication date: Available online 20 December 2019Source: The Lancet HIVAuthor(s): Rachel K Scott (Source: The Lancet HIV)
Source: The Lancet HIV - December 21, 2019 Category: Infectious Diseases Source Type: research

Trends in post-partum viral load among women living with perinatal HIV infection in the USA: a prospective cohort study
Publication date: Available online 20 December 2019Source: The Lancet HIVAuthor(s): Kunjal Patel, Brad Karalius, Kathleen Powis, Deborah Kacanek, Claire Berman, Anna-Barbara Moscicki, Mary Paul, Katherine Tassiopoulos, George R Seage, HIV/AIDS Cohort Study (PHACS)SummaryBackgroundSmall studies reported poor post-partum outcomes among young women living with perinatal HIV infection who are now ageing into adulthood and becoming pregnant. For targeted clinical intervention, we sought to identify women in this population at risk of poor post-partum virological control.MethodsWe abstracted data on pregnancy history for women l...
Source: The Lancet HIV - December 21, 2019 Category: Infectious Diseases Source Type: research

Key populations and power: people-centred social innovation in Asian HIV services
Publication date: Available online 7 December 2019Source: The Lancet HIVAuthor(s): Fan Yang, Rena Janamnuaysook, Mark A Boyd, Nittaya Phanuphak, Joseph D TuckerSummaryKey populations increasingly lead the design, implementation, and evaluation of HIV services, which provides an opportunity to make them more people-centred. Despite many challenges, a strong argument that these populations must have a greater role in HIV service planning, development, and delivery worldwide exists. This Viewpoint focuses on Asia, where key populations have advocated for legal reform, engaged vulnerable groups to decrease stigma, co-created i...
Source: The Lancet HIV - December 8, 2019 Category: Infectious Diseases Source Type: research

Circulating resistance to first-line HIV drug regimens
Publication date: Available online 7 December 2019Source: The Lancet HIVAuthor(s): Collins C Iwuji, Mark J Siedner (Source: The Lancet HIV)
Source: The Lancet HIV - December 8, 2019 Category: Infectious Diseases Source Type: research

Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial
Publication date: Available online 7 December 2019Source: The Lancet HIVAuthor(s): Michael H Chung, Christine J McGrath, Ingrid A Beck, Molly Levine, Ross S Milne, Isaac So, Nina Andersen, Sandra Dross, Robert W Coombs, Bhavna Chohan, Nelly Yatich, Catherine Kiptinness, Samah R Sakr, James N Kiarie, Lisa M FrenkelSummaryBackgroundAlthough experts have recommended testing for pretreatment drug resistance (PDR) before antiretroviral therapy (ART) initiation, there is little evidence to support its implementation. We aimed to establish whether an inexpensive point mutation assay can improve virological suppression by identify...
Source: The Lancet HIV - December 8, 2019 Category: Infectious Diseases Source Type: research

Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme
Publication date: Available online 5 December 2019Source: The Lancet HIVAuthor(s): John Kinuthia, Jillian Pintye, Felix Abuna, Kenneth K Mugwanya, Harison Lagat, Dickens Onyango, Emily Begnel, Julia Dettinger, Jared M Baeten, Grace John-Stewart, Ajode C Aquino, Steve J Ochieng, Alice M Lipesa, Ambia L Naidu, Anastacia Kamau, Anne W Njoroge, Bernard O Okeah, Cecilia B Makabwa, Celestine C Atieno, Christine K IreriSummaryBackgroundPregnant women in settings with high HIV prevalence are at increased risk of HIV acquisition and subsequent vertical transmission. We implemented and evaluated a novel programme to provide pre-expo...
Source: The Lancet HIV - December 6, 2019 Category: Infectious Diseases Source Type: research

PrEP implementation in pregnant and post-partum women
Publication date: Available online 5 December 2019Source: The Lancet HIVAuthor(s): Dvora Joseph Davey, Landon Myer, Thomas Coates (Source: The Lancet HIV)
Source: The Lancet HIV - December 6, 2019 Category: Infectious Diseases Source Type: research

Correction to Lancet HIV 2019; 6: e760–68
Publication date: December 2019Source: The Lancet HIV, Volume 6, Issue 12Author(s): (Source: The Lancet HIV)
Source: The Lancet HIV - December 3, 2019 Category: Infectious Diseases Source Type: research

People ageing with HIV face an uncertain future
Publication date: December 2019Source: The Lancet HIV, Volume 6, Issue 12Author(s): Talha Burki (Source: The Lancet HIV)
Source: The Lancet HIV - December 3, 2019 Category: Infectious Diseases Source Type: research

HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use
Publication date: Available online 27 November 2019Source: The Lancet HIVAuthor(s): Johan Vekemans, William Snow, Patricia E Fast, Rachel Baggaley, Kundai Chinyenze, Martin H Friede, Peter Godfrey-Faussett, David C Kaslow, Helen ReesSummaryVarious long-awaited efficacy studies of vaccines and broadly neutralising antibodies for prevention of HIV are now well underway in highly endemic settings. One broadly neutralising monoclonal antibody is being assessed for proof of concept, and combinations are in the pipeline. Two multicomponent prime-and-boost vaccine regimens are being evaluated, one of which is designed for global ...
Source: The Lancet HIV - November 28, 2019 Category: Infectious Diseases Source Type: research

On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial
Publication date: Available online 26 November 2019Source: The Lancet HIVAuthor(s): Guillemette Antoni, Cécile Tremblay, Constance Delaugerre, Isabelle Charreau, Eric Cua, Daniela Rojas Castro, François Raffi, Julie Chas, Thomas Huleux, Bruno Spire, Catherine Capitant, Laurent Cotte, Laurence Meyer, Jean-Michel Molina, Jean-Pierre Aboulker, Nathalie Bajos, Jean-Guy Baril, Michel Besnier, Johan Binesse, Diane CaretteSummaryBackgroundANRS IPERGAY found that on-demand pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus emtricitabine was associated with an 86% relative reduction of HIV-1 ...
Source: The Lancet HIV - November 27, 2019 Category: Infectious Diseases Source Type: research